Analysis of globotriaosylceramide (Gb 3 ) isoforms/analogs in unfractionated leukocytes, B lymphocytes and monocytes from Fabry patients using ultra-high performance liquid chromatography/tandem mass spectrometry
- 1 July 2018
- journal article
- research article
- Published by Elsevier in Analytica Chimica Acta
- Vol. 1015, 35-49
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- Tandem Mass Spectrometry Quantitation of Lyso‐Gb3 and Six Related Analogs in Plasma for Fabry Disease PatientsCurrent Protocols in Human Genetics, 2016
- Metabolomic Discovery of Novel Urinary Galabiosylceramide Analogs as Fabry Disease BiomarkersJournal of the American Society for Mass Spectrometry, 2015
- Urinary biomarker investigation in children with Fabry disease using tandem mass spectrometryClinica Chimica Acta, 2015
- LC–MS/MS analysis of plasma lyso-Gb3 in Fabry diseaseClinica Chimica Acta, 2012
- Fabry disease, enzyme replacement therapy and the significance of antibody responsesJournal of Inherited Metabolic Disease, 2011
- Leukocyte perturbation associated with Fabry diseaseJournal of Inherited Metabolic Disease, 2009
- Proposed high‐risk screening protocol for Fabry disease in patients with renal and vascular diseaseJournal of Inherited Metabolic Disease, 2009
- Cellular and tissue localization of globotriaosylceramide in Fabry diseaseVirchows Archiv, 2007
- Development of a filter paper method potentially applicable to mass and high‐risk urinary screenings for Fabry diseaseJournal of Inherited Metabolic Disease, 2006
- Measurement of urinary CDH and CTH by tandem mass spectrometry in patients hemizygous and heterozygous for Fabry diseaseJournal of Inherited Metabolic Disease, 2005